Trial Profile
Randomised phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with EGFR mutant non-squamous non small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Sep 2014
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms BAGEL study
- 01 Sep 2014 Status changed from not yet recruiting to recruiting, as per University Hospital Medical Information Network - Japan record.
- 14 May 2014 New trial record